[Melanoma: Cellular and vaccinal immunotherapy]

Area of Science:

• Immunology
• Oncology
• Dermatology

Context:

• Melanoma's immune system role enables therapeutic vaccination and cellular immunotherapy.
• Tumor-infiltrating lymphocytes (TILs) and melanoma antigen identification are key to these treatments.
• Current immunotherapies yield durable responses but have inadequate response rates.

Purpose:

• Investigate the role of the tumor microenvironment in melanoma immune tolerance.
• Identify mechanisms by which melanoma cells induce an immunotolerant environment.
• Enhance the effectiveness of cytotoxic T lymphocytes against melanoma.

Summary:

• Melanoma cells create an immunotolerant tumor microenvironment, hindering cytotoxic T lymphocyte (CTL) effectiveness.
• Therapeutic strategies include adjuvant approaches, lymphodepletion, antigen selection, and combining cellular therapy with monoclonal antibodies.
• Future directions involve adjuvant strategies for early-stage disease and combination treatments for metastatic melanoma.

Impact:

• Improved understanding of melanoma immune evasion mechanisms.
• Development of more effective melanoma immunotherapies.
• Identification of predictive biomarkers for patient response to treatment.